BioNTech, which hopes the whole world with the mRNA-based vaccine it has developed in the coronavirus epidemic, has made a remarkable announcement. In the statements made by the company, it was stated that a new vaccine was produced with the mRNA technique. This vaccine, named BNT122, seems to be a hope for colon cancer if it can be approved.
According to the statements made by the company, phase-2 studies of the BNT122 vaccine have started. Studies conducted in the USA, Germany, Belgium and Spain with the participation of around 200 patients focus on understanding whether cancer-causing tumors reappear in the body and whether it is related to the effectiveness of the vaccine.
Vaccine may not be limited to colon cancer
BioNTech explained that new treatment methods are needed because colon cancer is both the most common and the second most deadly cancer type, and the BNT122 vaccine is a result of this. If the studies are successful and the vaccine is put into use, it seems that deaths due to colon cancer can be prevented.
Although BioNTech’s studies have come to the fore with colon cancer, it is possible that the vaccine developed will be a solution to more cancer types. Because the company is trying to use the same vaccine for other types of cancer. As a result of the studies, a few years from now, the possibility of drawing our blood in the cancer gene may have disappeared completely.
34639
